A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma
NCT06019637 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2025-01-15
Summary
A long-term safety study in Brazilian patients with a confirmed diagnosis of Spinal Muscular Atrophy (SMA) treated with Onasemnogene Abeparvovec (Zolgensma®)
Conditions
- Spinal Muscular Atrophies
Interventions
- OTHER
-
Onasemnogene Abeparvovec
Retrospective and prospective observational study. There is no treatment allocation.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 0 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-22
- Primary Completion
- 2038-09-30
- Completion
- 2038-09-30
Countries
- Brazil
Study Locations
More Related Trials
-
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
NCT04488133 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
NCT02292537 ·Status: COMPLETED ·Phase: PHASE3
-
Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study
NCT04404764 ·Status: COMPLETED
-
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
NCT02386553 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT06191354 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
NCT02052791 ·Status: COMPLETED ·Phase: PHASE1
-
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
NCT03505099 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
NCT04729907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876 ·Status: RECRUITING ·Phase: PHASE3
-
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT04042025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
NCT02024932 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
NCT01703988 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
NCT01494701 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
NCT05901987 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
NCT04089566 ·Status: COMPLETED ·Phase: PHASE3
-
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
NCT02594124 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
NCT07070999 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT05789758 ·Status: RECRUITING
-
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT05839145 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
NCT06421831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Antisense Oligonucleotide for Spinal Muscular Atrophy
NCT05187260 ·Status: UNKNOWN
-
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
NCT02628743 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
NCT01753076 ·Status: COMPLETED ·Phase: PHASE2